Siegel, Corey

Siegel C. Evaluating a Prediction Tool and Decision Aid for Patients with Crohn's Disease - Final Report. (Prepared by Dartmouth College under Grant No. R01 HS021747). Rockville, MD: Agency for Healthcare Research and Quality, 2019.

Siegel CA, Horton H, Siegel LS, et al. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther 2016 Jan;43(2):262-71. PMID: 26567467.

Siegel CA, Lofland JH, Naim A, et al. Novel statistical approach to determine inflammatory bowel disease: patients' perspectives on shared decision making. Patient 2016 Feb;9(1):79-89. PMID: 25963447.

Thompson KD, Connor SJ, Walls DM, et al. Patients with ulcerative colitis are more concerned about complications of their disease than side effects of medications. Inflamm Bowel Dis 2016 Apr;22(4):940-7. PMID: 26950308.

Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn’s disease: a network meta-analysis. Gastroenterology 2015;148(2):344–54. PMID: 25448924.

Shah ED, Siegel CA, Chong K, et al. Patients with Crohn’s disease are more likely to remain on biologics than immunomodulators: a meta-analysis of treatment durability. Dig Dis Sci 2015;60(8):2408–18. PMID: 25772778.

Bressler B, Siegel CA. Beware of the swinging pendulum: anti-tumor necrosis factor monotherapy vs combination therapy for inflammatory bowel disease. Gastroenterology 2014 Apr;146(4):884-7.

Dulai PS, Siegel CA, Dubinsky MC. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2013 Dec;19(13):2927-36.